GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chugai Pharmaceutical Co Ltd (TSE:4519) » Definitions » EV-to-FCF

Chugai Pharmaceutical Co (TSE:4519) EV-to-FCF

: 23.04 (As of Today)
View and export this data going back to 1956. Start your Free Trial

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Chugai Pharmaceutical Co's Enterprise Value is 円7,734,385 Mil. Chugai Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was 円335,667 Mil. Therefore, Chugai Pharmaceutical Co's EV-to-FCF for today is 23.04.

The historical rank and industry rank for Chugai Pharmaceutical Co's EV-to-FCF or its related term are showing as below:

TSE:4519' s EV-to-FCF Range Over the Past 10 Years
Min: 14.78   Med: 42.17   Max: 2782.11
Current: 21.92

During the past 13 years, the highest EV-to-FCF of Chugai Pharmaceutical Co was 2782.11. The lowest was 14.78. And the median was 42.17.

TSE:4519's EV-to-FCF is ranked worse than
50.88% of 513 companies
in the Drug Manufacturers industry
Industry Median: 21.66 vs TSE:4519: 21.92

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-23), Chugai Pharmaceutical Co's stock price is 円5150.00. Chugai Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was 円197.800. Therefore, Chugai Pharmaceutical Co's PE Ratio for today is 26.04.


Chugai Pharmaceutical Co EV-to-FCF Historical Data

The historical data trend for Chugai Pharmaceutical Co's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chugai Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.65 60.35 27.42 29.21 23.98

Chugai Pharmaceutical Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.21 20.33 32.72 36.63 23.98

Competitive Comparison

For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chugai Pharmaceutical Co EV-to-FCF Distribution

For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Chugai Pharmaceutical Co's EV-to-FCF falls into.



Chugai Pharmaceutical Co EV-to-FCF Calculation

Chugai Pharmaceutical Co's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=7734384.868/335667
=23.04

Chugai Pharmaceutical Co's current Enterprise Value is 円7,734,385 Mil.
Chugai Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円335,667 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chugai Pharmaceutical Co  (TSE:4519) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Chugai Pharmaceutical Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=5150.00/197.800
=26.04

Chugai Pharmaceutical Co's share price for today is 円5150.00.
Chugai Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円197.800.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Chugai Pharmaceutical Co EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Chugai Pharmaceutical Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Chugai Pharmaceutical Co (TSE:4519) Business Description

Traded in Other Exchanges
Address
1-1 Nihonbashi-Muromachi 2-Chome, Nihonbashi Mitsui Tower (Reception15F), Chuo-ku, Tokyo, JPN, 103-8324
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding Ltd, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and COVID-19.

Chugai Pharmaceutical Co (TSE:4519) Headlines

No Headlines